News

Filter

Current filters:

Lupuzor

Pipeline innovation bodes well for systemic lupus erythematosus market

18-02-2014

While the systemic lupus erythematosus (SLE) treatment market is predominantly limited to GlaxoSmithKline’s…

AmgenAnti-Arthritics/RheumaticsBenlystaGlaxoSmithKlineImmuPharmaLupuzorLymphoCideMarkets & MarketingPharmaceuticalRituxanRoche

ImmuPharma’s Lupuzor OKed to start Phase III and fast-tracked by US FDA

03-11-2011

UK-based ImmuPharma plc (LSE:IMM), which last month regained rights to its investigational lupus drug…

ImmuPharmaLupuzorPharmaceuticalRare diseasesRegulationResearch

COMPANY SPOTLIGHT

Menarini

Back to top